All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
EBMT 2026 | Top abstracts: What’s hot in GvHD?
To help navigate the exciting content being presented at the the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), March 22–25, 2026, Madrid, ES, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD.
Oral presentations: Monday, March 23
| Abstract | Title | Presenter | Time (CET) |
| GS2-8 | MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Final results from the ARES phase III trial | Florent Malard | 17:33–17:42 |
Oral presentations: Tuesday, March 24
| Abstract | Title | Presenter | Time (CET) |
| OS11-03 | T cell resistance to glucocorticoids in graft-versus-host disease | Andrew McIntyre | 11:18–11:27 |
| OS12-07 | Post-transplant cyclophosphamide dose reduction within an entirely calcineurin and mTOR inhibitor-free GvHD prophylaxis regimen: Interim results of the ABC phase I-IIb trial | A Samer Al-Homsi | 15:24–15:33 |
| Paed3-07 | Real-world outcomes of mesenchymal stromal cell therapy in heavily pre-treated paediatric patients with refractory acute graft-versus-host disease | Peter Bader | 15:24–15:33 |
Oral presentations: Wednesday, March 25
| Abstract | Title | Presenter | Time (CET) |
| OS14-01 | Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allo-HSCT plus Tac/Mtx for GvHD prevention in randomized phase 3 clinical trial (Precision-T) | Arpita Gandhi | 08:30–08:39 |
| OS16-01 | Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety | Jianyun Liao | 12:30–12:39 |
| OS16-04 | Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Updated safety analysis of a randomized, phase 2 study | Amandeep Salhotra | 12:57–13:06 |
| OS16-05 | Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GvHD: Update from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP | Udo Holtick | 13:06–13:15 |
| OS16-06 | A comprehensive analysis of axatilimab in patients with chronic graft-versus-host disease and related bronchiolitis obliterans syndrome: Integrated analysis from 2 clinical studies | Zachariah DeFilipp | 13:15–13:24 |
| OS16-07 | Chronic graft-versus-host disease: Real-world outcomes and efficacy of ruxolitinib compared with conventional treatments | Thomas Sau Yan Chan | 13:24–13:33 |
Posters
| Abstract | Title | Presenter | Date and time (CET) |
| B005 | Key results from the CHRONOS multicentre retrospective cohort study describing patient outcomes in third-line acute gastrointestinal GvHD | Johannes Clausen | Sunday, March 22, 08:30–18:00 |
| B006 | Phase 2 study of extracorporeal photopheresis with [methoxsalen] plus standard steroid treatment for high-risk acute graft-versus-host disease | Francis Ayuketang Ayuk | Sunday, March 22, 08:30–18:00 |
| B007 | Clinical outcomes among patients with chronic graft-versus-host disease treated with axatilimab: Analysis of an expanded access program | Anthony Stein | Sunday, March 22, 08:30–18:00 |
| B016 | The combination of ruxolitinib and extracorporeal photopheresis is a highly effective second line treatment for chronic graft-versus-host disease | Nikolett Wohner | Sunday, March 22, 08:30–18:00 |
| B018 | Mesenchymal stromal cells for the treatment steroid refractory graft-versus-host disease in children | Krzysztof Czyzewski | Sunday, March 22, 08:30–18:00 |
| B033 | Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study | María Sola Soto | Sunday, March 22, 08:30–18:00 |
| B048 | Efficacy and safety of belumosudil-ECP (extracorporeal photopheresis) combination therapy in refractory chronic graft-versus-host disease (cGvHD) and correlation with cytokin kinetic: A single-center retrospective study | Chiusolo Patrizia | Sunday, March 22, 08:30–18:00 |
| B055 | Real-world efficacy and toxicity profile of ruxolitinib in pediatric acute and chronic graft-versus-host disease: A multicenter retrospective study | Andrea Buonsante | Sunday, March 22, 08:30–18:00 |
| P123 | Faecal microbial transplantation for graft-versus-host disease | Andrea Henden | Sunday, March 22, 08:30–18:00 |
| P128 | Etanercept as second-line therapy for steroid-refractory GvHD: Feasibility, safety, and outcomes | Michel Lu | Sunday, March 22, 08:30–18:00 |
| P131 | ECP based combinations for treating acute and chronic graft versus host disease | Simon Bulley | Sunday, March 22, 08:30–18:00 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In steroid-refractory acute GvHD, which factor most strongly limits your use of mesenchymal stromal cells in routine clinical practice?